Main menu

Accurate somatic small variant discovery for multiple sequencing technologies with DeepSomatic

  • Published on: October 16 2025
  • Source: Nature Biotechnology

Cancer is a highly heterogeneous disease, with thousands of somatic variants across different cells, requiring accurate characterisation. Typically, cancer research relies on short-read sequencing, but limitations of this approach include the inability to resolve repetitive or complex regions. With Oxford Nanopore sequencing, any length of DNA can be sequenced and analysed, revealing areas that were previously inaccessible. Here, the authors present DeepSomatic, a somatic small variant caller that combines long- and short-read data to accurately detect somatic small nucleotide variants and indels. They found that this bioinformatic tool outperformed other somatic variant callers, achieving consistently high F1-scores.

‘DeepSomatic’s models specific to FFPE and WES also prove to outperform other variant callers that were not specifically trained for these data types’

Park and Cook et al. Nature Biotechnology (2025)

Sample type: glioblastoma tumour tissue and matched peripheral blood mononuclear cells

Kit: Ligation Sequencing Kit

Authors: Jimin Park, Daniel E. Cook, Pi-Chuan Chang, Alexey Kolesnikov, Lucas Brambrink, Juan Carlos Mier, Joshua Gardner, Brandy McNulty, Samuel Sacco, Ayse Keskus, Asher Bryant, Tanveer Ahmad, Jyoti Shetty, Yongmei Zhao, Bao Tran, Giuseppe Narzisi, Adrienne Helland, Byunggil Yoo, Irina Pushel, Lisa A. Lansdon, Chengpeng Bi, Adam Walter, Margaret Gibson, Tomi Pastinen, Midhat S. Farooqi, Nicolas Robine, Karen H. Miga, Andrew Carroll, Mikhail Kolmogorov, Benedict Paten, Kishwar Shafin

入门指南

购买 MinION 启动包 Nanopore 商城 测序服务提供商 全球代理商

联系我们

知识产权 Cookie 政策 企业报告 隐私政策 条件条款 前瞻性陈述

关于 Oxford Nanopore

联系我们 领导团队 媒体资源和联系方式 投资者 在 Oxford Nanopore 工作 BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Chinese flag